JAK抑制剂芦可替尼治疗中国骨髓纤维化患者的疗效和安全性：A2202随访一年结果

OBJECTIVE: To evaluate the efficacy and safety of ruxolitinib in Chinese myelofibrosis patients. METHODS: This study enrolled 63 Chinese patients (32 males and 31 females) in total, whose median age was 55 (25–79) years. The initial dose of ruxolitinib was 30mg/d (25 patients) with a baseline of PLT...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2016
Materias:
论著
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7364878/
https://www.ncbi.nlm.nih.gov/pubmed/27801315
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.10.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7364878/
https://www.ncbi.nlm.nih.gov/pubmed/27801315
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.10.007

Ejemplares similares